SHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of AgeX Therapeutics, Inc. (NYSE American – AGE)

BALA CYNWYD – August 30, 2023 /NewsFile/ – Law office of Brodsky & Smith announces that it is investigating potential claims against the Board of Directors of AgeX Therapeutics, Inc. (“AgeX” or the “Company”) (NYSE American – AGE) for possible breaches of fiduciary duty and other violations of federal and state law in connection with the merger of the Company with Serina Therapeutics, Inc. (“Serina”). Under the terms of the merger agreement, Serina will merge with a wholly owned subsidiary of AgeX, and stockholders of Serina will receive shares of AgeX common stock. Pre-merger AgeX stockholders are expected to own approximately 25% of the newly combined company while pre-merger Serina stockholders are expected to own approximately 75% of the newly combined company.

The investigation concerns whether the AgeX Board breached its fiduciary duties to shareholders by failing to conduct a fair process, including whether Serina is paying fair value to shareholders of the Company.

If you own shares of AgeX stock and wish to discuss the legal ramifications of the investigation, or have any questions, you may e-mail or call the law office of Brodsky & Smith who will, without obligation or cost to you, attempt to answer your questions. You may contact Jason L. Brodsky, Esquire, or Marc L. Ackerman by email at, or call toll free 855-576-4847.

Brodsky & Smith is a litigation law firm with extensive expertise representing shareholders throughout the nation in securities and class action lawsuits. The attorneys at Brodsky & Smith have been appointed by numerous courts throughout the country to serve as lead counsel in class actions and have successfully recovered millions of dollars for our clients and shareholders. Attorney advertising. Prior results do not guarantee a similar outcome.